Size, Share & Industry Analysis, By Product Type (Disposable Automatic Biopsy Guns, Reusable Automatic Biopsy Guns), By Application (Breast Biopsy, Prostate Biopsy, Liver & Kidney Biopsy, Lung Biopsy, Lymph Node & Other Soft Tissue), By Guidance (Ultrasound-Guided, CT-Guided, Stereotactic / X-ray Guided, MRI-Compatible), By End User (Hospitals, Diagnostic & Imaging Centers, Ambulatory Surgical Centers, Specialty Clinics), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Automatic Biopsy Gun Market was valued at USD 782.6 million in 2025 and is estimated at USD 827.2 million in 2026. Revenue is projected to reach USD 1.29 billion in 2034, a 5.7% CAGR over 2026–2034.
Automatic biopsy guns are spring-actuated or mechanically triggered instruments that obtain a core of tissue for histopathology. The relevant product revenue comprises sterile disposable automatic core biopsy instruments and reusable spring-loaded guns, together with integral cutting needles supplied as a unit. It excludes vacuum-assisted breast-biopsy consoles, fine-needle aspiration syringes, imaging scanners, laboratory pathology charges, and separately invoiced coaxial introducers. U.S. FDA records distinguish these biopsy instruments under product code KNW and regulation 21 CFR 876.1075, allowing direct identification of the regulated device class.
Biopsy device design influences sample acquisition when a target lies close to vessels, pleura, or other vulnerable tissue. Merit Medical offers automatic, delayed, and zero-throw settings on its Achieve device, while BD supplies Marquee disposable instruments with selectable firing options. IZI Medical lists 12G, 14G, 16G, 18G and 20G Quick-Core Auto configurations, allowing operators to select needle size for tissue type and planned imaging guidance.
The International Agency for Research on Cancer recorded 2.3 million new female breast cancers in 2022, and the World Health Organization identified lung cancer as the most frequently diagnosed malignancy that year. Suspicious imaging findings can require a core specimen to establish histology and guide treatment selection, although not every cancer case leads to an automatic-gun procedure. The National Cancer Institute distinguishes core-needle sampling from fine-needle aspiration, and the Canadian Cancer Society describes core biopsy as an outpatient procedure performed under imaging or palpation guidance.
Competition extends from global interventional-device companies to regional needle manufacturers. FDA decisions during 2025 and 2026 covered Bard Marquee, Argon ZeniCore, Zhejiang Curaway automatic instruments and Promisemed automatic biopsy needles. These clearances confirm product availability and competitive entry but do not independently establish manufacturer sales shares. North America represented an estimated 42% of 2025 revenue in the scenario allocation, with demand supported by image-guided breast and soft-tissue biopsy services and procurement of single-use sterile instruments.
Source: FDA 2026 Argon clearance; IARC 2025 breast burden; Merit Achieve; Canadian Cancer Society.
Revenue includes new automatic soft-tissue core-biopsy gun units and disposable automatic instruments sold to clinical providers. Reusable gun replacement is counted once at equipment sale; separately sold needles, coaxial introducers, imaging systems, pathology testing and vacuum-assisted consoles are excluded to prevent double counting.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Product Type | Disposable Automatic Biopsy Guns; Reusable Automatic Biopsy Guns |
| By Application | Breast Biopsy; Prostate Biopsy; Liver & Kidney Biopsy; Lung Biopsy; Lymph Node & Other Soft Tissue |
| By Guidance | Ultrasound-Guided; CT-Guided; Stereotactic / X-ray Guided; MRI-Compatible |
| By End User | Hospitals; Diagnostic & Imaging Centers; Ambulatory Surgical Centers; Specialty Clinics |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Germany; China; India; Japan; Brazil; Mexico; United Arab Emirates; South Africa |
| Key Market Players | Becton, Dickinson and Company; Merit Medical Systems, Inc.; Argon Medical Devices, Inc.; IZI Medical Products; Geotek Medical; M.D.L. S.r.l.; Zhejiang Curaway Medical Technology Co., Ltd.; Promisemed Hangzhou Meditech Co., Ltd.; Xaga Surgical AB; Aster Medispro Private Limited |
Automatic firing requires an instrument that mechanically advances the stylet and cutting cannula to acquire a core specimen. The reusable-gun category counts the durable actuator at initial sale and replacement, not its separately purchased disposable needles. The disposable category counts single-use automatic devices with their integral cutting mechanisms; semi-automatic products are included only where a spring-powered firing stage is present. The U.S. FDA classification under 21 CFR 876.1075 identifies the regulated instrument category without implying that every KNW clearance represents an identical design.
The Application axis assigns each instrument sale to the procedure for which it is purchased or consumed, while Guidance assigns the same revenue to the imaging approach used during the procedure. End User identifies the purchasing clinical setting rather than the treating physician specialty. These independent views each allocate 100% of the same manufacturer-level device revenue; hospital procedure charges, imaging guidance fees, pathology analysis and downstream cancer treatment are outside the market boundary.
IARC estimated 2.3 million new female breast cancers in 2022, while WHO identified lung, breast and colorectal cancers as major contributors to the global diagnostic burden. A suspicious lesion often requires histologic confirmation before treatment planning, creating repeated purchases of sterile automatic core devices. The National Cancer Institute distinguishes a wide-needle core biopsy from fine-needle aspiration because the former removes tissue for microscopic examination. Growth in breast screening and interventional radiology can therefore increase demand for disposable firing instruments, although screening volumes must not be treated as direct device sales.
The Canadian Cancer Society describes core biopsy in offices, clinics and hospitals as an outpatient procedure, generally under local anesthetic. Frimley Health NHS Foundation Trust explains that stereotactic breast biopsy uses a spring-loaded needle device to take several tissue samples. Such workflows favor compact instruments that can be prepared quickly, operated with one hand and supplied sterile. IZI Medical sells Quick-Core Auto in single-use sterile packages, while BD offers Marquee disposable instruments in multiple gauges. Outpatient utilization raises the importance of per-procedure replenishment, packaging availability and distributor reliability.
Merit Medical lists automatic, delayed and zero-throw modes for Achieve, enabling the operator to inspect needle placement before releasing the cutting cannula. IZI Quick-Core Auto offers comparable selectable firing modes, while BD Magnum reusable guns provide 15 mm and 22 mm penetration-depth settings. The resulting control matters when a lesion is adjacent to a vessel, pleural surface or another structure that should not be crossed. Product selection therefore depends on throw geometry, target depth and compatibility with ultrasound or CT guidance rather than on acquisition price alone.
FDA cleared the Zhejiang Curaway automatic core-biopsy family in January 2025 and the Bard Marquee disposable instrument in July 2025. During 2026, the agency also cleared Argon ZeniCore, Promisemed VeriEcto and another Curaway automatic instrument. Each decision reflects substantial equivalence for the identified device and intended use, not evidence of clinical superiority or a quantified market share. Additional qualified manufacturers can expand distributor choices and tender competition, while purchasers continue to assess sterility, sample quality, reliability and training requirements.
Argon Medical describes Pro-Mag Ultra as a reusable gun with a service program and durable firing mechanism; Geotek lists MAXICORE-M as a sterilizable reusable device. Reusable instruments spread acquisition cost over repeated procedures but require compatible needles, reprocessing and maintenance. Disposable systems eliminate gun reprocessing between patients and provide a new firing assembly for each case. BD Magnum and Argon Pro-Mag Ultra have reusable mechanisms requiring compatible needles and service protocols, whereas BD Marquee is a single-use device that shifts instrument expenditure to each procedure.
Source: IARC; National Cancer Institute; Canadian Cancer Society; Frimley Health NHS; Merit Medical; IZI Medical; BD; Argon Medical; FDA 510(k) database.
Merit Achieve supports automatic, delayed and zero-throw operation within one device, and IZI Quick-Core Auto supplies three firing modes with a 25 mm throw and 20 mm notch. Programmable devices let physicians tailor tissue capture to lesion position without changing the whole instrument. BD Marquee offers two firing modules, while BD Magnum reusable systems allow penetration-depth selection. These specifications increase differentiation in a mechanically mature category, particularly for imaging-guided procedures where the cutting cannula must be positioned carefully before activation.
IZI Medical states that Quick-Core coaxial sets include an introducer and blunt-tip stylet, and its conventional Quick-Core system can obtain multiple samples through one access site. Argon BioPince products also offer optional coaxial introducers for guided soft-tissue biopsy. A coaxial pathway can reduce repeated skin punctures when pathology requires several cores, although the introducer is a separately identified accessory rather than an automatic-gun revenue item. Hospitals buying automatic instruments increasingly evaluate device compatibility with existing coaxial sets and ultrasound visibility during placement.
IZI lists Quick-Core Auto sizes from 12G to 20G, with multiple needle lengths, while Geotek ESTACORE offers 14G through 20G configurations. BD Marquee provides separate 16G and 18G disposable products for soft-tissue sampling. Wider gauge choices allow interventional teams to balance specimen volume against access constraints in breast, liver, kidney, lung and lymph-node procedures. Stocking multiple lengths also increases distributor inventory complexity, encouraging hospital standardization around a smaller number of qualified suppliers that can maintain dependable sterile supply.
The European Commission states that four EUDAMED modules became mandatory from 28 May 2026, including actor registration, device registration, notified-body certificates and market surveillance. Automatic biopsy-gun suppliers selling into the European Union must maintain the relevant medical-device documentation, traceability and post-market processes. This creates a procurement distinction between manufacturers with established regulatory infrastructure and lower-cost entrants still building compliance systems. European buyers also evaluate single-use packaging and reprocessing instructions, particularly when comparing disposable systems with reusable guns and compatible needles.
Geotek Medical supplies Turkish-made disposable ESTACORE automatic biopsy needles and reusable MAXICORE guns, while M.D.L. in Italy markets Palium reusable instruments and compatible FastCut needles. Zhejiang Curaway and Promisemed obtained U.S. FDA clearances for automatic biopsy instruments during 2025–2026, indicating manufacturing competition beyond incumbent U.S. suppliers. Mechanical firing systems remain differentiated by safety locks, echogenic markings, specimen notches and compatibility with hospital workflow. Distributor support and consistent quality can therefore preserve purchasing preference even where lower-priced alternatives enter tenders.
Automatic biopsy gun market revenue is allocated between disposable self-contained firing devices and reusable actuator guns. The categories refer to the instrument sold, not to disposable replacement needles purchased for a reusable gun. FDA Marquee clearances and Argon Pro-Mag product documentation confirm that both purchasing models remain commercially active.
Disposable automatic instruments represented an estimated ~74% of 2025 revenue. BD Marquee is sold as a disposable core biopsy instrument, and IZI Quick-Core Auto is supplied sterile for single use. Each clinical procedure requires a new device, creating recurring unit purchases and reducing the need for reprocessing of a firing assembly. Hospital procurement decisions also depend on gauge choice, shelf life and predictable sterile packaging.
BD Magnum and Argon Pro-Mag Ultra are reusable automatic firing platforms that accept compatible disposable needles. Geotek MAXICORE-M can be sterilized and offers selectable sample depth. Reusable guns are attractive where procedure volumes justify instrument maintenance and needle standardization, but their purchase frequency is lower than single-use products. Manufacturer revenue counts the gun sale rather than adding all future compatible-needle expenditure.
Disposable systems transfer much of the cost to each procedure, whereas reusable systems involve instrument acquisition, reprocessing, service and compatible-needle inventory. Argon identifies maintenance support for Pro-Mag Ultra, and BD specifies one-handed cocking for Magnum. Departments compare sample reliability, training burden and total cost, not just unit price. Disposable demand is expected to retain value leadership while reusable devices continue in established high-volume workflows.
Product configuration will remain differentiated by throw length, firing control, compatibility and sterile supply. FDA clearances for disposable and reusable families show that procurement continues across both models, with newer suppliers competing for hospital tenders.
Application allocation assigns each automatic instrument to the clinical procedure that consumes or procures it. Breast, prostate, lung, liver and kidney, and lymph-node or other soft-tissue biopsies have distinct lesion-access and specimen requirements, but all use histologic core acquisition.
Breast biopsy represented an estimated ~37% of 2025 revenue. IARC documented 2.3 million new female breast cancers worldwide in 2022, and NCI describes core needle biopsy as a route to histologic confirmation. Breast imaging centers often require multiple samples after suspicious mammography or ultrasound findings. The Frimley Health NHS pathway identifies spring-loaded sampling under stereotactic guidance, supporting use of compact automatic devices in outpatient breast assessment.
Xaga Surgical obtained FDA clearance for its Forsvall biopsy needle system in February 2025, demonstrating ongoing product development for prostate tissue sampling. Urology services require consistent specimen collection across targeted and systematic cores, with device choice influenced by transperineal or transrectal access. The automatic-gun boundary covers the firing instrument, excluding imaging and histopathology charges.
Argon BioPince Ultra is described for percutaneous liver and kidney biopsy and offers adjustable throw lengths. Lung sampling requires careful needle placement near pleura and vessels, where delayed firing and controlled advancement may influence device choice. CT- and ultrasound-guided procedures use disposable sterile equipment across hospital radiology departments. FDA-classified biopsy instrument sales exclude separately billed imaging and pathology charges.
Core biopsy of lymph nodes and other soft-tissue masses can be performed with ultrasound guidance when lesion position permits. IZI Medical supplies multiple needle gauges and lengths for soft-tissue targets, and the NCI defines core biopsy as removing tissue with a wide needle for microscopic examination. IZI needle catalogs offer multiple lengths and echogenic markings for varied lesion access.
Cancer burden supports recurrent demand across applications, but lesion-specific guidance, needle gauge and patient setting determine actual instrument choice. Each product sale is allocated to one principal application, preventing the same multipurpose instrument from being counted under several procedures.
Guidance segmentation separates ultrasound-guided, CT-guided, stereotactic or X-ray-guided, and MRI-compatible automatic core biopsy devices by their principal intended procedure. Each instrument sale belongs to a single principal guidance channel even when labeling permits multiple imaging approaches.
Ultrasound guidance is the largest modality because clinicians can view the needle during many breast, liver, kidney and superficial soft-tissue procedures. Merit Achieve highlights one-handed operation for ultrasound-guided biopsy, while IZI Quick-Core uses echogenic needle markings to improve visibility. The ACR 2026 personnel requirements emphasize training in breast ultrasound instrumentation and image-guided biopsy. Guidance revenue covers the automatic gun, not the ultrasound scanner or physician service.
CT guidance is important for lung, retroperitoneal and selected deep abdominal lesions. FDA documentation for ZeniCore describes advancing the biopsy device toward the target with ultrasound, fluoroscopy or CT guidance. Longer needles and coaxial access can help operators position a cutting device before sampling.
Frimley Health NHS describes stereotactic breast core biopsy using X-ray localization and a spring-loaded device to obtain tissue. The modality is used when a suspicious mammographic abnormality cannot be targeted easily with ultrasound. Breast imaging capacity supports device demand, while the market boundary excludes separately powered vacuum-assisted biopsy consoles. Device suppliers compete through reliable firing, sample quality and compatibility with sterile breast-procedure kits.
MRI-guided breast interventions require materials and instruments compatible with the imaging environment. Mammotome announced U.S. FDA clearance of an in-room MR vacuum-assisted breast biopsy system in March 2026; that console is an adjacent product and is not counted as an automatic gun. Only an automatic core-firing instrument specifically intended for MRI-guided use enters this segment. This distinction prevents transferring vacuum-assisted system revenue into the spring-loaded biopsy-gun market.
Guidance choice depends on lesion visibility, anatomy and available radiology capacity. Manufacturers with multiple gauge and length options can supply more than one clinical workflow without treating a single instrument sale as multiple guidance revenues.
End-user segmentation attributes automatic biopsy-gun purchases to hospitals, diagnostic and imaging centers, ambulatory surgical centers, or specialty clinics. Purchases are attributed to the buying facility, regardless of whether a clinician also practices at another location.
Hospitals are the largest purchasing group because interventional radiology, surgery, urology and oncology departments use core biopsy devices for a broad range of lesions. FDA-cleared product families include multiple gauge and length combinations that hospital supply teams can standardize across departments. Larger institutions often compare reusable-gun maintenance with disposable sterile workflow costs. Procurement contracts, training requirements and stocking reliability can influence supplier choice as strongly as individual device specifications.
The Canadian Cancer Society states that core biopsy can be performed in clinics and outpatient settings, including procedures guided by ultrasound, X-ray or CT. Dedicated breast imaging centers require reliable sterile instruments for scheduled biopsy lists and may prioritize quick setup and sample handling. BD Marquee and Merit Achieve offer device options for this environment. Only the purchasing facility receives the device allocation; referrals alone do not create additional equipment sales.
Ambulatory centers can perform selected image-guided or clinician-guided biopsies without overnight admission. One-handed automatic firing and compact disposable packaging reduce setup complexity in procedure rooms with limited instrument-reprocessing infrastructure. Access to radiology guidance and pathology collection remains necessary, and those service charges are excluded from the automatic-gun market.
Urology, breast and selected oncology clinics may purchase automatic core instruments for in-office tissue acquisition. Xaga Forsvall was cleared for prostate biopsy in 2025, while IZI Quick-Core offers needle configurations used for soft-tissue procedures. Specialty practices frequently have narrower case mixes than hospitals and can standardize a small selection of gauges. Reusable instruments may be economical in established workflows, while single-use guns reduce the need for equipment servicing and sterilization.
Hospitals should retain the largest allocation; outpatient centers can expand where local imaging enables core sampling. Each transaction is assigned to the actual purchasing setting rather than counted again through referral pathways.
Regional demand reflects cancer diagnostic pathways, access to image-guided procedures, disposable-device procurement and medical-device regulation. North America leads the scenario revenue allocation; European MDR compliance and Asia-Pacific manufacturing competition influence supplier selection elsewhere.
North America represented an estimated ~42% of 2025 automatic biopsy-gun revenue, supported by established breast imaging, pathology and interventional radiology services. The FDA maintains an active Class II 510(k) pathway for biopsy instruments under regulation 21 CFR 876.1075. The agency cleared Bard Marquee in July 2025, Argon ZeniCore in February 2026 and further automatic core devices in August 2026. These decisions show active product competition, although clearance does not measure market share. Hospital buyers compare disposable sterile instruments with reusable firing guns, while outpatient centers favor compact one-handed systems. The Canadian Cancer Society describes core biopsy in offices, clinics and hospitals and distinguishes vacuum-assisted biopsy from conventional core needles. That distinction is important for revenue measurement because vacuum consoles and tissue-processing fees are excluded.
FDA 510(k) K250032 granted substantial-equivalence clearance to Bard Marquee on 10 July 2025, while K252795 cleared Argon ZeniCore on 23 February 2026. Both records identify biopsy instruments under product code KNW. U.S. procurement includes hospital radiology, breast imaging and specialist biopsy services. The FDA decisions establish regulated product availability but provide no audited sales allocation, so manufacturer shares cannot be inferred from the number of clearances.
Source: U.S. FDA.
The Canadian Cancer Society describes outpatient core biopsy under ultrasound, X-ray or CT guidance, with tissue sent to a laboratory for diagnosis. It distinguishes conventional core needles from vacuum-assisted sampling, supporting separate purchasing categories for the instruments. Canadian providers therefore purchase biopsy equipment across imaging departments, clinics and hospitals, but the published clinical pathway does not disclose annual automatic-gun procurement volumes or average realized device prices.
Source: Canadian Cancer Society.
European hospitals purchase automatic biopsy guns within a medical-device regulatory environment shaped by Regulation (EU) 2017/745. The European Commission states that four EUDAMED modules became mandatory from 28 May 2026, including actor and device registration and market-surveillance functions. Suppliers must maintain appropriate technical documentation and post-market processes for products placed on the European Union market. Product choice differs across breast, urology and interventional radiology departments, with reusable guns competing against sterile single-use devices. Italian manufacturer M.D.L. supplies Palium reusable instruments and compatible needles, showing regional production alongside imported products. The United Kingdom maintains clinical protocols for stereotactic breast biopsy, while Germany and other EU countries use medical-device procurement systems that emphasize traceability and tender terms. These regulatory requirements influence distribution costs without demonstrating a numeric regional revenue share.
Frimley Health NHS Foundation Trust published a patient pathway approved 1 May 2025 describing stereotactic breast core biopsy with a spring-loaded needle device. The pathway uses X-ray localization, local anesthetic and several tissue cores, with specimen examination performed separately. Such procedures create demand for sterile biopsy instruments and related accessories in breast assessment units, but hospital procedure reimbursement is not equivalent to device manufacturer revenue.
Source: Frimley Health NHS.
German device distributors operate under EU Regulation 2017/745, and the European Commission identifies EUDAMED registration and surveillance modules as mandatory from 28 May 2026. German hospital tenders for automatic core biopsy devices must consider product traceability, sterile labeling and compatibility with clinical procedures. The regulation applies to the product supply chain; it does not imply that every biopsy device has the same firing mechanism or that reusable and disposable guns share identical maintenance requirements.
Source: European Commission.
Asia-Pacific combines large diagnostic patient populations with local production of automatic biopsy instruments. Zhejiang Curaway received FDA clearance for automatic core devices in January 2025 and August 2026, while Promisemed received clearance for VeriEcto automatic needles in May 2026. These records document export-oriented device capabilities in China rather than quantified domestic consumption. India has local manufacturers such as Aster Medispro, which offers a reusable spring-loaded biopsy gun with selectable sampling depths. Japan’s National Cancer Center describes tissue and cell examination after suspicious breast imaging as part of diagnostic confirmation. Hospitals and imaging centers across the region face different capital budgets and distributor networks, encouraging both premium programmable systems and lower-cost reusable devices. The scenario expects rising procedural demand, but no numeric regional share beyond the largest market is published.
The FDA cleared Zhejiang Curaway automatic biopsy instruments on 24 January 2025 and 28 August 2026, confirming regulatory submissions from a Hangzhou manufacturer. Promisemed also received U.S. clearance for VeriEcto automatic biopsy needles on 12 May 2026. These clearances support evidence of Chinese manufacturing capacity and product variety; they do not establish Chinese hospital sales or the share of the global automatic-gun market attributable to Chinese manufacturers.
Source: U.S. FDA.
Japan’s National Cancer Center explains that suspected breast malignancies require examination of cells or tissue under a microscope to establish diagnosis after imaging. This pathway creates demand for core-biopsy instruments where clinicians select tissue rather than cytology sampling. Japanese facilities also use ultrasound, mammography and other imaging to locate lesions. The public clinical guidance does not specify the proportion of cases using spring-loaded automatic guns instead of vacuum-assisted devices.
Source: National Cancer Center Japan.
Latin American demand depends on access to breast imaging, pathology services and minimally invasive biopsy procedures. Brazil’s National Cancer Institute describes diagnostic and treatment pathways that depend on tumor characterization, while Mexico’s National Cancer Institute emphasizes biopsy to confirm breast cancer and assess tumor biology. These clinical requirements support the use of tissue-sampling devices, but national screening statistics cannot be converted directly into automatic-gun sales. Regional distributors often supply disposable biopsy instruments alongside imaging and surgical consumables, with purchase decisions influenced by import prices, sterile packaging and maintenance availability. Hospitals in major cities have broader interventional radiology capabilities than smaller facilities, creating uneven demand for programmable firing modes and specialized needle lengths. The revenue boundary remains the automatic device itself rather than downstream pathology or oncology treatment.
Brazil’s INCA updated its professional breast cancer guidance in 2025 and emphasized rapid investigation of suspicious findings, including pathology and tumor receptor characterization. Automatic core biopsy devices can support the tissue-acquisition stage of that pathway. The same guidance addresses screening and treatment, which are separate services and cannot be counted as biopsy-gun manufacturer sales. Purchasing opportunities depend on hospital imaging capacity and availability of trained procedural staff.
Source: Brazil INCA.
Mexico’s National Cancer Institute identifies biopsy as the route to confirming breast cancer and evaluating biological markers after suspicious mammography or examination. Mexico’s INCan clinical pathway therefore requires tissue collection before microscopic confirmation. Automatic gun purchases depend on whether lesions are sampled in hospitals, specialist clinics or imaging centers, and the equipment cost is distinct from laboratory analysis. The institute’s guidance does not quantify annual national procurement or the share of automatic devices within all biopsy techniques.
Source: Mexico INCan.
Middle East and Africa includes high-resource tertiary hospitals and systems with limited imaging and pathology capacity. The IARC reports substantial global differences in cancer diagnosis and mortality across human-development groups, which influence access to early tissue confirmation. Automatic core biopsy guns are relevant where clinicians can localize lesions by ultrasound or CT and send specimens to pathology laboratories. Hospitals with established interventional radiology departments can purchase programmable devices, while smaller facilities may favor reusable equipment or basic disposable configurations. Imported instruments require dependable distributor supply, sterile inventory and training in specimen handling. No audited country-level biopsy-gun revenue bridge is available from the inspected institutional evidence, so the scenario assigns only qualitative regional positioning.
Hospitals in the United Arab Emirates operate within a wider Gulf network of specialist cancer and imaging services. WHO and IARC data identify breast and lung cancers as major contributors to the worldwide diagnostic burden, making tissue confirmation relevant to oncology pathways. Automatic biopsy guns require trained operators and suitable imaging guidance, and procurement costs include sterile replenishment or reusable-gun maintenance. No public manufacturer report isolates UAE automatic core-biopsy instrument revenue.
Source: IARC.
South African providers face uneven access to imaging, pathology and interventional radiology across public and private facilities. IARC’s global cancer assessment identifies disproportionate mortality burdens in lower-resource settings, reinforcing the importance of timely tissue diagnosis. Automatic biopsy devices can support outpatient core sampling when ultrasound or CT and specimen processing are available. These clinical requirements do not demonstrate a particular national device share, and vacuum-assisted breast biopsy equipment remains outside the automatic-gun revenue boundary.
Source: IARC.
Automatic core biopsy instruments are regulated medical devices whose permitted use, sterility and operating instructions must be verified at the product level. U.S. FDA clearances establish substantial equivalence for specified designs, while European rules govern device registration and post-market responsibilities.
| Regulatory record | Date | Device or requirement | Commercial relevance |
|---|---|---|---|
| FDA K241793 | 24 Jan 2025 | Curaway automatic/semi-automatic core biopsy instruments | Additional cleared device configurations |
| FDA K242128 | 27 Feb 2025 | Xaga Forsvall prostate biopsy gun and needle | Specialized prostate sampling platform |
| FDA K250032 | 10 Jul 2025 | Bard Marquee disposable core biopsy instrument | Established disposable instrument clearance |
| FDA K252795 | 23 Feb 2026 | Argon ZeniCore automatic biopsy instrument | New automatic device configurations |
| FDA K261196 | 12 May 2026 | Promisemed VeriEcto automatic biopsy needles | Broader qualified supplier set |
| FDA K260517 | 28 Aug 2026 | Curaway automatic core biopsy instrument | Further 2026 clearance activity |
| EU EUDAMED | 28 May 2026 | Mandatory initial registration and surveillance modules | Device traceability and compliance costs |
FDA regulation 21 CFR 876.1075 classifies biopsy instruments under a Class II framework, and product code KNW appears on the inspected automatic-core device clearances. The 2025 Bard Marquee decision is a special 510(k), while Argon ZeniCore and Curaway submissions are traditional 510(k) records. These regulatory pathways establish substantial equivalence to legally marketed predicates for identified configurations. They do not constitute a head-to-head efficacy ranking, nor do they disclose net selling prices or annual units.
Product instructions determine whether a firing instrument is disposable or reusable, what needle sizes and penetration depths are permitted, and which imaging environments are appropriate. Merit Achieve provides three firing modes, BD Magnum is a reusable actuator and IZI Quick-Core Auto is supplied sterile for single use. BD Magnum and IZI Quick-Core Auto specify different reusable and single-use handling requirements. The European Commission states that EUDAMED registration and surveillance obligations expanded in May 2026, adding compliance considerations for suppliers entering EU hospital tenders.
Core tissue acquisition must be distinguished from vacuum-assisted biopsy and fine-needle aspiration. The National Cancer Institute describes core biopsy as wide-needle tissue removal, whereas vacuum-assisted breast biopsy uses suction and a rotating cutter. Mammotome’s March 2026 clearance of an MRI-room vacuum-assisted system is therefore adjacent innovation, not automatic spring-gun revenue. Procedure choice remains the clinician’s decision based on lesion location, sample needs, imaging visibility and safety precautions in the device labeling.
Automatic biopsy gun supply spans diversified medical-device manufacturers and focused needle specialists. Purchasing criteria include firing reliability, specimen quality, sterile packaging, needle compatibility, training and distribution support. No audited supplier-by-supplier automatic-gun revenue split is available from the inspected disclosures.
BD supplies Magnum reusable and Marquee disposable instruments, while Merit Achieve provides programmable automatic, delayed and zero-throw operation. Their broad clinical distribution supports hospital standardization across biopsy workflows.
Argon offers Pro-Mag reusable guns and BioPince tissue sampling devices; IZI Quick-Core Auto is a sterile programmable system. Device choice varies with throw control, gauge, and coaxial compatibility.
Geotek markets disposable ESTACORE and reusable MAXICORE devices, M.D.L. offers Palium guns, and Aster lists spring-loaded reusable biopsy equipment. Geotek and M.D.L. product portfolios broaden distributor options for disposable and reusable devices.
FDA clearances in 2025–2026 identify Curaway automatic instruments, Promisemed VeriEcto needles and Xaga Forsvall prostate biopsy equipment. FDA clearance identifies the regulated device but does not disclose supplier sales.
BD maintains two distinct purchasing models through Magnum reusable guns and Marquee disposable instruments. Magnum offers 15 mm or 22 mm penetration depths, while Marquee includes alternative firing modes and multiple needle gauges. Merit Achieve competes on selectable automatic, delayed and zero-throw firing. These features can affect needle-position control and staff training, particularly in interventional radiology and breast imaging. Their product catalogs establish competitive participation without revealing a market-share ranking.
Argon Medical markets Pro-Mag Ultra as a serviceable reusable instrument and supplies BioPince full-core biopsy systems. IZI Medical lists Quick-Core Auto in several gauge and length combinations with optional coaxial introducers. Both suppliers address hospitals requiring procedure-specific choices rather than a single universal device. Coaxial accessories, replacement needles and service contracts may contribute to company revenue, but the defined market counts only the automatic gun or integral disposable firing instrument.
Geotek Medical supplies ESTACORE disposable automatic needles and MAXICORE reusable guns, while Italy-based M.D.L. lists Palium reusable equipment. Aster Medispro markets a spring-loaded biopsy gun in India. Their catalogs show competition on needle geometry, depth selection, sterile packaging and purchase price. Regional manufacturers may gain tenders when established device specifications can be met at lower procurement cost, although product-page availability alone does not establish a delivered unit or annual revenue total.
FDA cleared Curaway’s automatic biopsy family in January 2025 and another automatic device in August 2026. The agency also cleared Promisemed VeriEcto in May 2026 and Xaga’s Forsvall prostate biopsy gun in February 2025. These dated records support active product registration by manufacturers in China and Sweden. Hospital procurement will still depend on distribution contracts, clinician familiarity, compatibility with available imaging guidance and reliable supply. The published regional and segment shares are scenario estimates rather than audited company allocations.
24 January 2025: FDA granted substantial-equivalence clearance K241793 to Zhejiang Curaway Medical Technology for automatic and semi-automatic core biopsy instruments and disposable coaxial needles. The decision documents an additional qualified manufacturing platform for soft-tissue biopsy and confirms that several instrument configurations fall under regulation 21 CFR 876.1075. The clearance is a regulatory event, not a measure of U.S. sales volume. Source
27 February 2025: FDA cleared Xaga Surgical’s Forsvall biopsy needle system for prostate biopsy under K242128. The decision covers a named biopsy gun and compatible needle, establishing a specialized product configuration within the automatic-core market. Urology buyers can evaluate its procedure fit alongside existing reusable and disposable systems; the FDA record does not report comparative specimen performance or commercial revenue. Source
10 July 2025: FDA cleared the Bard Peripheral Vascular Marquee disposable core biopsy instrument and kit through K250032. The filing identifies a Class II biopsy instrument and a special 510(k) route. BD continues to list Marquee disposable configurations in multiple gauges and lengths, supporting sterile single-use procurement for hospitals and imaging centers without demonstrating a numeric market share. Source
23 February 2026: FDA cleared Argon Medical Devices’ ZeniCore automatic biopsy instrument under K252795. The submission identifies disposable instrument configurations and uses Tru-Core II and Marquee devices among its predicates. The decision confirms a new regulated automatic sampling platform and additional product choice for interventional clinicians, but it does not establish superiority over predicate devices or realized selling prices. Source
12 May 2026: FDA issued clearance K261196 for Promisemed Hangzhou Meditech’s VeriEcto automatic biopsy needles. The filing places the device in the biopsy-instrument category under regulation 21 CFR 876.1075. The clearance adds another qualified manufacturer to international supply competition and demonstrates continuing product registration activity; it does not disclose the company’s shipment volume or share of global device sales. Source
28 August 2026: FDA cleared Zhejiang Curaway’s automatic core biopsy instrument under K260517, following the company’s earlier January 2025 device clearance. The new decision shows continued registration of automatic biopsy products and may broaden purchasing alternatives for distributors and hospitals. Its commercial significance depends on actual product availability, clinical adoption and supplier contracts, none of which is quantified in the FDA record. Source
Automatic biopsy gun market revenue is projected to increase from USD 827.2 million in 2026 to USD 1.29 billion by 2034, a 5.7% CAGR. Growth is tied to recurring core-biopsy instrument use, replacement purchases and wider availability of regulated automatic systems.
| Forecast factor | Current evidence | Expected effect through 2034 |
|---|---|---|
| Cancer tissue diagnosis | IARC reports high global breast and lung cancer burden | Sustains demand for core tissue acquisition |
| Single-use purchasing | BD Marquee and IZI Quick-Core Auto supplied as disposables | Supports recurring sterile-device sales |
| Programmable firing | Merit Achieve offers three firing modes | Differentiates premium instrument configurations |
| Regulatory entrants | FDA clearances for Curaway, Promisemed and Argon | Expands qualified supplier choice |
| Outpatient care | Canadian Cancer Society describes clinic-based core biopsy | Increases importance of compact procedure devices |
| EU traceability | EUDAMED registration obligations expanded in May 2026 | Raises supplier documentation requirements |
Cancer screening and lesion evaluation provide the clinical demand base, but device sales depend on the number of cases proceeding to tissue sampling. IARC estimates for breast and lung cancer show a large diagnostic burden, while the National Cancer Institute distinguishes core tissue biopsy from fine-needle aspiration. Hospitals and imaging centers choose between automatic firing, vacuum assistance and other methods according to lesion and specimen needs. Forecast revenue therefore follows procedure mix and procurement rather than simply applying cancer incidence growth to a device price.
Sterile disposable systems are expected to retain the largest share of automatic-gun revenue. BD Marquee and IZI Quick-Core Auto are marketed for single use, creating repeated instrument purchases across biopsy lists. Reusable guns remain relevant where departments can maintain actuators and purchase compatible needles separately. Argon Pro-Mag Ultra and Geotek MAXICORE illustrate that alternative, with maintenance and sterilization requirements affecting total cost. Neither business model can be valued by adding separately invoiced needle sales to the automatic-gun numerator.
Product differentiation will remain centered on firing control, sample geometry, ultrasound visibility and needle selection. Merit Achieve provides delayed and zero-throw modes, and IZI Quick-Core Auto spans multiple gauges and lengths. FDA clearances in 2025 and 2026 demonstrate continuing product registrations by established and emerging manufacturers. More qualified options may intensify tenders and constrain average selling prices, while clinically valued features can sustain premium pricing in difficult lesion-access procedures.
Regional expansion depends on hospital imaging capacity and the availability of pathology laboratories. North America is the largest scenario market, while EU device registration requirements shape European supply and Asian manufacturers add competitive capacity. Latin American and African demand remains linked to access to trained clinicians and diagnostic services. The forecast does not assume that every newly detected cancer case uses an automatic gun, and it excludes vacuum-assisted breast biopsy consoles, radiology charges and downstream pathology revenue. This exclusive boundary preserves comparability across the 2025 base and 2034 forecast.
Coverage includes automatic soft-tissue core biopsy instruments sold to clinical providers, with independent segmentation of device configuration, procedure application, imaging guidance and purchasing setting.
Global automatic biopsy-gun revenue is **USD 782.6 million for 2025** under the defined manufacturer-level device boundary. The figure covers disposable automatic core instruments and reusable firing guns, while excluding vacuum-assisted biopsy consoles, separately invoiced needles, radiology charges and laboratory pathology fees. The 2026 estimate is USD 827.2 million.
The market is projected to grow at **5.7% CAGR from 2026 to 2034**, reaching USD 1.29 billion. Recurring sterile-device purchases, cancer tissue diagnosis and image-guided outpatient procedures support demand. Price competition among qualified suppliers and continued use of reusable guns moderate revenue growth.
Disposable automatic biopsy guns lead with an estimated **~74% of 2025 revenue**. BD Marquee and IZI Quick-Core Auto are sold as single-use sterile instruments, eliminating the need to reprocess the firing assembly between patients. Reusable platforms such as BD Magnum remain important where hospitals maintain established gun-and-needle workflows.
Breast biopsy is the leading application, accounting for an estimated **~37% of 2025 device revenue**. IARC recorded 2.3 million new female breast cancers in 2022, and suspicious breast imaging findings often require core tissue confirmation. Not every detected lesion requires an automatic gun, because vacuum-assisted and other sampling methods are also used.
A fully automatic gun advances the stylet and cutting cannula through a triggered firing sequence. Semi-automatic or delayed systems allow the operator to position or release one component before completing the cut. Merit Achieve and IZI Quick-Core Auto provide selectable modes, while BD Magnum is a reusable firing platform with adjustable penetration depth.
North America is the largest region, with an estimated **~42% share of 2025 revenue**. U.S. hospital and outpatient biopsy services purchase regulated instruments, and the FDA cleared multiple automatic device families during 2025–2026. The regional percentage is a scenario allocation rather than an audited supplier-revenue split.
Yes, multiple automatic core biopsy instruments have U.S. FDA 510(k) clearances under regulation **21 CFR 876.1075**. Recent examples include Bard Marquee in July 2025, Argon ZeniCore in February 2026 and Curaway automatic instruments in August 2026. Clearance confirms substantial equivalence for identified devices; it does not guarantee suitability for every patient or procedure.
Ultrasound helps operators locate a visible lesion and observe needle advancement during tissue sampling. Merit Achieve highlights one-handed use for ultrasound-guided biopsy, and IZI products use echogenic needle features to improve visualization. Ultrasound is one of several guidance methods, alongside CT and stereotactic X-ray imaging.
Some automatic biopsy guns are reusable, including BD Magnum, Argon Pro-Mag Ultra and Geotek MAXICORE models. They require compatible needles and the manufacturer-specified reprocessing or maintenance process. Disposable alternatives such as BD Marquee and IZI Quick-Core Auto are supplied for single-patient use, so the correct choice depends on clinical workflow and total procedure cost.
Verified suppliers include BD, Merit Medical, Argon Medical, IZI Medical, Geotek, M.D.L., Zhejiang Curaway, Promisemed, Xaga Surgical and Aster Medispro. FDA clearance records verify named instruments for several manufacturers, while product catalogs document firing modes and gauge choices. The FDA decisions do not disclose audited sales for any of the named manufacturers.
Constraints include hospital purchasing budgets, price competition, sterile inventory requirements, reusable-gun maintenance and availability of trained image-guided biopsy staff. Vacuum-assisted systems may be preferred for selected breast lesions, reducing the portion of biopsy activity using spring-loaded guns. EU device registration and U.S. FDA compliance add documentation requirements for suppliers.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.